References
1. Billot K, Coquil C, Villiers B, Josselin-Foll B, Desban N, Delehouze C, Oumata N, Le Meur Y, Boletta A, Weimbs T, Grosch M, Witzgall R, Saunier S, Fischer E, Pontoglio M, Fautrel A, Mrug M, Wallace DP, Tran PV, Trudel M, Bukanov NO, Ibraghimov-Beskrovnaya O, Meijer L. Casein kinase 1? and 1? as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8. Am J Physiol Renal Physiol. 2018 Mar 14. doi: 10.1152/ajprenal.00489.2017. [Epub ahead of print] PubMed PMID: 29537311.
2. You T, Wang Y, Li K, Zhang D, Wei H, Luo Y, Li H, Lu Y, Su X, Kuang Z. Crystal structure of SPSB2 in complex with a rational designed RGD-containing cyclic peptide inhibitor of SPSB2-iNOS interaction. Biochem Biophys Res Commun. 2017 Jul 29;489(3):346-352. doi: 10.1016/j.bbrc.2017.05.122. Epub 2017 May 24. PubMed PMID: 28549582.
3. Skovira JW, Wu J, Matyas JJ, Kumar A, Hanscom M, Kabadi SV, Fang R, Faden AI. Cell cycle inhibition reduces inflammatory responses, neuronal loss, and cognitive deficits induced by hypobaria exposure following traumatic brain injury. J Neuroinflammation. 2016 Dec 1;13(1):299. PubMed PMID: 27903275; PubMed Central PMCID: PMC5131508.
4. Husson H, Moreno S, Smith LA, Smith MM, Russo RJ, Pitstick R, Sergeev M, Ledbetter SR, Bukanov NO, Lane M, Zhang K, Billot K, Carlson G, Shah J, Meijer L, Beier DR, Ibraghimov-Beskrovnaya O. Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Hum Mol Genet. 2016 Jun 1;25(11):2245-2255. Epub 2016 Apr 5. PubMed PMID: 27053712; PubMed Central PMCID: PMC5081056.
